A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

Test-Retest Reproducibility of 18F-AV-1451 Injection for Brain Imaging of Tau in Healthy Volunteers and Cognitively Impaired Subjects.

This study will test if two flortaucipir PET scans up to 4 weeks apart in healthy volunteers, MCI and AD subjects provide the same results.

Inclusion Criteria:

• Healthy Volunteers

  • Male or female subjects ≥ 50 years of age
  • Mini-mental state examination (MMSE) ≥ 29

• MCI Subjects

  • Male or female subjects ≥ 50 years of age
  • MMSE ≥ 24
  • Have MCI consistent with National Institute on Aging-Alzheimer's Association (NIA-AA) working group's diagnostic guidelines for AD
  • Have a study partner that can report on subject's activities of daily living

• Probable AD Subjects

  • Male or female subjects ≥ 50 years of age
  • MMSE > 10
  • Meet clinical criteria for probable AD based on the NIA-AA working group's diagnostic guidelines for AD
  • Have a study partner that can report on subject's activities of daily living

Exclusion Criteria:

• Current clinically significant psychiatric disease
• Evidence of structural brain abnormalities
• Evidence of dementing illness other than AD
• Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes
• Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
• History of alcohol or substance abuse or dependence
• Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception
• Have received or participated in a trial with investigational medications in the past 30 days
• have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session.